Arix Bioscience Supports Artios Pharma, a New Biotech Company
Focused on DNA Damage Response
LONDON, 21 SEPTEMBER 2016: Arix Bioscience PLC (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has participated, along with leading European and US healthcare investors, in a Series A financing of Artios Pharma Ltd., a new private company focused on the DNA Damage Response (DDR). Artios has announced the launch of the company, and successful completion of its fundraise of $33.2 million (£25 million).
Dr. Jonathan Tobin of Arix Bioscience, has joined the Board of Artios and will provide strategic input to the company.
Arix Bioscience has joined a strong syndicate of leading European and US life science investors including SV Life Sciences, Merck Ventures, Imperial Innovations, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Proceeds of the financing will be used to build a high value pipeline of DDR therapies, and to progress Artios' lead programme, Pol-theta, in-licensed from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), into the clinic.
DDR therapies have demonstrated significant patient benefit in the treatment of cancer, following the recent success of AstraZeneca's PARP inhibitor Lynparza™ (olaparib). Artios aims to develop a novel, first-in-class DDR pipeline that will target tumour DNA repair mechanisms to selectively kill tumour cells through a concept known as "synthetic lethality".
Dr. Joe Anderson, Chief Executive Officer of Arix Bioscience, said: "We are delighted to support Artios in this new and exciting area of drug discovery and development. Our participation in the financing of Artios highlights Arix's continued commitment to support emerging innovative companies, and we believe that Artios has launched at the optimal time and has the potential to transform cancer therapy through DDR therapies."
Dr. Niall Martin, Chief Executive Officer of Artios, said: "We are pleased to have the financial and strategic support of Arix as one of our world-class investors. Artios is committed to establishing DDR inhibitors as first-line therapies for the treatment of cancer."
About Arix Bioscience PLC and Group
Arix Bioscience PLC is a global healthcare and life science company. Headquartered in London and with an office in New York, Arix Bioscience sources and develops businesses addressing medical innovation at all stages of development and is supported with access to breakthrough academic science.
Further information: www.arixbioscience.com
About Artios Pharma Ltd.
Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company's investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
About DNA Damage Response (DDR)
DNA Damage occurs in cells throughout the body every day. To counteract the harmful effects that DNA damage can cause, the human body possesses a network of DNA repair pathways, which act to correct the damage. This process is known as the DNA Damage Response (DDR). Defects in the body's DDR can lead to an increased risk of cancer. Human cells have multiple DNA repair pathways, but in cancer cells, some of these pathways are lost, which result in genetic instability. Changes to DNA repair pathways can also drive the growth of tumours. By inhibiting DDR in cancer cells that have impaired repair pathways, scientists can selectively kill cancerous cells. DDR inhibitors, therefore, have the potential to act as: single agents that selectively kill tumour cells through synthetic lethality; adjunctive therapy to overcome resistance to current cytotoxics, and potentiating agents to radiotherapy and novel therapies including immune-oncology treatments.
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan, Melissa Gardiner, Cameron Standage
Tel: +44 (0)20 3709 5700
Email: [email protected]
This information is provided by RNS